Thermo Fisher Scientific (TMO) : Compass Capital Management Inc reduced its stake in Thermo Fisher Scientific by 0.57% during the most recent quarter end. The investment management company now holds a total of 145,925 shares of Thermo Fisher Scientific which is valued at $21,446,597 after selling 836 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on May 3, 2016.Thermo Fisher Scientific makes up approximately 4.25% of Compass Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Mariner Investment Group sold out all of its stake in TMO during the most recent quarter. The investment firm sold 1,500 shares of TMO which is valued $220,455.Rand Wealth reduced its stake in TMO by selling 973 shares or 4.4% in the most recent quarter. The Hedge Fund company now holds 21,153 shares of TMO which is valued at $3,051,320. Thermo Fisher Scientific makes up approx 0.42% of Rand Wealth’s portfolio.Appleton Partners Incma boosted its stake in TMO in the latest quarter, The investment management firm added 533 additional shares and now holds a total of 67,592 shares of Thermo Fisher Scientific which is valued at $9,925,885. Thermo Fisher Scientific makes up approx 1.93% of Appleton Partners Incma’s portfolio.Yhb Investment Advisors reduced its stake in TMO by selling 17,740 shares or 18.32% in the most recent quarter. The Hedge Fund company now holds 79,108 shares of TMO which is valued at $11,617,010. Thermo Fisher Scientific makes up approx 3.08% of Yhb Investment Advisors’s portfolio.
Thermo Fisher Scientific opened for trading at $148.36 and hit $148.8899 on the upside on Tuesday, eventually ending the session at $148.83, with a gain of 0.93% or 1.37 points. The heightened volatility saw the trading volume jump to 14,71,477 shares. Company has a market cap of $58,566 M.
On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.